Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
ONCOLOGIST, cilt.28, sa.7, ss.596-603, 2023 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 28 Sayı: 7
- Basım Tarihi: 2023
- Doi Numarası: 10.1093/oncolo/oyad102
- Dergi Adı: ONCOLOGIST
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
- Sayfa Sayıları: ss.596-603
- Anahtar Kelimeler: prostate cancer, castration-sensitive, abiraterone acetate, non-steroidal anti-androgens, ANDROGEN, ENZALUTAMIDE, SURVIVAL, THERAPY, MANAGEMENT, RESISTANCE, DOCETAXEL, MECHANISM, LIVER
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ankara Üniversitesi Adresli: Evet
Özet
This review evaluates the pooled data from phase III trials of androgen-receptor signaling inhibitors in patients with metastatic castration-sensitive prostate cancer to dissect the impact of abiraterone acetate plus prednisone versus non-steroidal anti-androgens on overall survival for metastatic castration-sensitive prostate cancer with visceral metastasis.